A review of adherence to drug therapy in patients with overactive bladder

被引：112

作者：

Basra, Ramandeep K. ^{[1
]}

Wagg, Adrian ^{[2
]}

Chapple, Christopher ^{[3
]}

Cardozo, Linda ^{[4
]}

Castro-Diaz, David ^{[6
]}

Pons, Montserrat Espuna ^{[7
]}

Kirby, Mike ^{[5
]}

Milsom, Ian ^{[8
]}

Vierhout, Mark ^{[9
]}

Van Kerrebroeck, Philip ^{[10
]}

Kelleher, Con ^{[1
]}

机构：

[1] Guys St Thomas NHS Fdn Trust, Sheffield, S Yorkshire, England

[2] Univ Coll London, Sheffield, S Yorkshire, England

[3] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England

[4] Kings Coll Hosp London, London, England

[5] Univ Hertfordshire, Ctr Res Primary & Community Care, Hatfield AL10 9AB, Herts, England

[6] Univ Canarias, Tenerife, Spain

[7] Univ Barcelona, Barcelona, Spain

[8] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden

[9] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[10] Univ Hosp Maastricht, Maastricht, Netherlands

来源：

BJU INTERNATIONAL | 2008年 / 102卷 / 07期

关键词：

adherence; overactive bladder; pharmacotherapy;

D O I：

10.1111/j.1464-410X.2008.07769.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Drug therapy for overactive bladder (DAB) is associated with improvements in symptoms and quality of life, but the short- and long-term adherence and persistence is suboptimal. In this review we outline methods of measuring, and factors affecting, adherence to pharmacatherapy in patients with CAB. Clinical practice suggests that adherence rates reported in clinical trials art much greater than in real practice. Factors affecting adherence include psychological and social variables that might alter patients' perception of the benefits of taking medication, and the effect of comorbidity and polypharmacy. Whilst there is some evidence that lack of efficacy and side-effects are contributory, these additional factors are also important.

引用

页码：774 / 779

页数：6

共 25 条

[1] Twelve-month treatment of overactive bladder - Efficacy and tolerability of tolterodine [J].

Abrams, P ;

Malone-Lee, J ;

Jacquetin, B ;

Wyndaele, JJ ;

Tammela, T ;

Jonas, U ;

Wein, A .

DRUGS & AGING, 2001, 18 (07) :551-560

[2] Factors involved in the success of antimuscarinic treatment [J].

Abrams, P ;

Larsson, G ;

Chapple, C ;

Wein, AJ .

BJU INTERNATIONAL, 1999, 83 :42-47

[3]

Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052

[4]

Abrams P, 2000, AM J MANAG CARE, V6, pS580

[5] Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: A longitudinal cohort study [J].

Balkrishnan, R ;

Bhosle, MJ ;

Camacho, FT ;

Anderson, RT .

JOURNAL OF UROLOGY, 2006, 175 (03) :1067-1071

[6] Attitudes to prescribed medicines, and their influence on treatment compliance in OAB [J].

Basra, R. ;

Cortes, E. ;

Khullar, V. ;

Kelleher, C. .

EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) :202-202

[7] Transdermal oxybutynin: Sticking to the facts [J].

Cartwright, Rufus ;

Cardozo, Linda .

EUROPEAN UROLOGY, 2007, 51 (04) :907-914

[8] Effect of personal and cultural beliefs on medication adherence in the elderly [J].

Chia, Lichun Rebecca ;

Schlenk, Elizabeth A. ;

Dunbar-Jacob, Jacqueline .

DRUGS & AGING, 2006, 23 (03) :191-202

[9] Compliance in asthma [J].

Cochrane, GM ;

Horne, R ;

Chanez, P .

RESPIRATORY MEDICINE, 1999, 93 (11) :763-769

[10] Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: A one-year study [J].

Diokno A. ;

Sand P. ;

Labasky R. ;

Sieber P. ;

Antoci J. ;

Leach G. ;

Atkinson L. ;

Albrecht D. .

International Urology and Nephrology, 2002, 34 (1) :43-49

← 1 2 3 →